Figure 5

(A) Patients with high risk-scores tended to have higher LNM in GC patients than did those with low risk scores. (B) The four-miRNA signature can predict LNM in GC patients with higher AUC (p < 0.0001), indicating the considerable clinical value to predict LNM in GC patients. (C) miR-214/N stage signature can predict survival in GC patients with higher AUC (p = 0.00477), indicting the miR-214/N stage signature had better prognostic value than that of miR-214 or N stage alone for patients with gastric cancer. The combination of miRNAs (miR-27b and miR-214) (F, p = 0.0243) better predicted survival than miR-27b (D, p = 0.0403) and miR-214 (E, p = 0.0480) with respect to OS.